The results of our study are also consistent with the previous study by Sun et al. that reported a different treatment response that was explained by greater TP53 mutations in B/T, indicating that gemcitabine-based adjuvant therapy should be considered in treating B/T pancreatic cancer. The gene discussed is TP53; the disease is familial pancreatic carcinoma.